Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
…, S He, Z Wang, J Feng, C Lin, Y Ye… - National Science …, 2020 - academic.oup.com
Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has
been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to …
been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to …
[HTML][HTML] Diabetes promotes retinal vascular endothelial cell injury by inducing CCN1 expression
…, S Wen, R Peng, Y Nie, Y Lu, H Yang, Y Ye… - Frontiers in …, 2021 - frontiersin.org
Purpose: Diabetic retinopathy (DR) is one of the most common diabetic microvascular
complications. However, the pathogenesis of DR has not yet been fully elucidated. This study …
complications. However, the pathogenesis of DR has not yet been fully elucidated. This study …
Upper respiratory tract viral ribonucleic acid load at hospital admission is associated with coronavirus disease 2019 disease severity
X Guo, Y Jie, Y Ye, P Chen, X Li, Z Gao… - Open forum …, 2020 - academic.oup.com
Background The outbreak of coronavirus disease 2019 (COVID-19) has aroused global
public health concerns. Multiple clinical features relating to host profile but not for virus have …
public health concerns. Multiple clinical features relating to host profile but not for virus have …
[HTML][HTML] Efficacy and safety of all-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin in treatment-naive noncirrhotic HCV genotype 1 patients …
…, Y Zhao, Y Yu, J Jia, D Yang, L Chen, Y Ye… - Journal of clinical and …, 2019 - ncbi.nlm.nih.gov
Background and Aims: Ravidasvir (RDV) is a new generation pangenotypic hepatitis C virus
(HCV) NS5A inhibitor, with high barrier to baseline resistance-associated species. This is …
(HCV) NS5A inhibitor, with high barrier to baseline resistance-associated species. This is …
Decreases in Activated CD8+ T Cells in Patients with Severe Hepatitis B Are Related to Outcomes
Y Ye, J Liu, Q Lai, Q Zhao, L Peng, C Xie… - Digestive diseases and …, 2015 - Springer
Background Many studies on T helper (Th)1, Th2, T regulatory and Th17 cells have been
carried out in acute-on-chronic liver failure (ACLF). However, CD8 + T cell, as a main …
carried out in acute-on-chronic liver failure (ACLF). However, CD8 + T cell, as a main …
[HTML][HTML] Liver myofibroblasts up-regulate monocyte CD163 expression via PGE2 during hepatitis B induced liver failure
M Zhang, Y Ye, F Wang, J Zhu, Q Zhao… - Journal of translational …, 2014 - Springer
Background Although patients with liver failure exhibit a generalized inflammatory-imbalance
status, substantial evidence indicates that this immunosuppressive or anti-inflammatory …
status, substantial evidence indicates that this immunosuppressive or anti-inflammatory …
Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results
…, M Zhang, S Zhang, J Shang, W Lu, Y Ye… - Antiviral …, 2018 - journals.sagepub.com
Background In China, the clinical management of chronic hepatitis B (CHB) is complicated
by the use of various-nucleoside/nucleotide analogue (NUC) regimens in treatment-naive …
by the use of various-nucleoside/nucleotide analogue (NUC) regimens in treatment-naive …
[HTML][HTML] Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China
…, X Mao, J Lian, G Deng, Y Xin, Y Wang, Y Ye… - Infectious Diseases and …, 2023 - Springer
Introduction A pan-genotypic and effective treatment regimen for patients with chronic hepatitis
C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel …
C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel …
Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from …
…, J Sheng, Z Su, H Chen, E Dai, Y Ye… - Antiviral …, 2020 - journals.sagepub.com
Background In China, the optimal management of individuals living with chronic HBV infection
(CHB) remains an unmet need. The EVOLVE Study was a 5-year prospective, longitudinal…
(CHB) remains an unmet need. The EVOLVE Study was a 5-year prospective, longitudinal…
SBC (Sanhuang Xiexin Tang combined with Baihu Tang plus Cangzhu) alleviates NAFLD by enhancing mitochondrial biogenesis and ameliorating inflammation in …
…, ZHU Yanhua, CAI Mengyin, YE Yinong… - Chinese Journal of …, 2023 - Elsevier
In the context of non-alcoholic fatty liver disease (NAFLD), characterized by dysregulated
lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid …
lipid metabolism in hepatocytes, the quest for safe and effective therapeutics targeting lipid …